Link: Hospital acquired infections
The majority of newly introduced products and products in late stage development target gram-positive bacteria such as methicillin resistant Staphylococcus aureus (MRSA). However, the MRSA market is set to become increasingly crowded. Datamonitor believes there is a significant opportunity for new antibacterials which can treat multidrug resistant gram-negative organisms, a crucial unmet need for the hospital market. Johnson & Johnson looks best positioned here with two in-licensed compounds, doripenem and ceftobiprole set to be launched very soon.
